Tuberous sclerosis complex and fragile X syndrome are genetic diseases characterized by intellectual disability and autism. Because both syndromes are caused by mutations in genes that regulate protein synthesis in neurons, it has been hypothesized that excessive protein synthesis is one core pathophysiological mechanism of intellectual disability and autism. Using electrophysiological and biochemical assays of neuronal protein synthesis in the hippocampus of Tsc2 1/2 and Fmr1 2/y mice, here we show that synaptic dysfunction caused by these mutations actually falls at opposite ends of a physiological spectrum. Synaptic, biochemical and cognitive defects in these mutants are corrected by treatments that modulate metabotropic glutamate receptor 5 in opposite directions, and deficits in the mutants disappear when the mice are bred to carry both mutations. Thus, normal synaptic plasticity and cognition occur within an optimal range of metabotropic glutamate-receptor-mediated protein synthesis, and deviations in either direction can lead to shared behavioural impairments.
Tuberous sclerosis complex and fragile X syndrome are genetic diseases characterized by intellectual disability and autism. Because both syndromes are caused by mutations in genes that regulate protein synthesis in neurons, it has been hypothesized that excessive protein synthesis is one core pathophysiological mechanism of intellectual disability and autism. Using electrophysiological and biochemical assays of neuronal protein synthesis in the hippocampus of Tsc2 1/2 and Fmr1 2/y mice, here we show that synaptic dysfunction caused by these mutations actually falls at opposite ends of a physiological spectrum. Synaptic, biochemical and cognitive defects in these mutants are corrected by treatments that modulate metabotropic glutamate receptor 5 in opposite directions, and deficits in the mutants disappear when the mice are bred to carry both mutations. Thus, normal synaptic plasticity and cognition occur within an optimal range of metabotropic glutamate-receptor-mediated protein synthesis, and deviations in either direction can lead to shared behavioural impairments.
More than 1% of the human population has an autism spectrum disorder (ASD), and it has been estimated that over 50% of those with autism also have intellectual disability 1 . In most cases, the cause is unknown. However, genetically defined syndromes with increased prevalence of autism and intellectual disability offer an opportunity to understand the brain pathophysiology that manifests as ASD and intellectual disability, and this knowledge can suggest potential therapies. A case in point is fragile X syndrome (FXS), caused by silencing of the FMR1 gene and loss of the protein product, FMRP. Studies of the Fmr1 knockout (2/y) mouse revealed that in the absence of FMRP, protein synthesis is increased downstream of metabotropic glutamate receptor 5 (mGluR5). Diverse mutant phenotypes in fragile X animal models have been corrected by genetic or pharmacological inhibition of mGluR5, and preliminary human clinical trials using drugs that inhibit mGluR5 have shown promise 2 . Because several other syndromic forms of ASD and intellectual disability are associated with mutations of genes that regulate messenger RNA (mRNA) translation at synapses, it has been hypothesized that altered synaptic protein synthesis might contribute generally to the autistic phenotype, including intellectual disability 3 . The aim of the current study was to test the hypothesis that a mutation responsible for another genetic syndrome associated with ASD and intellectual disability-tuberous sclerosis complex (TSC)-produces abnormalities in synaptic protein synthesis and plasticity similar to fragile X. If this were the case, treatments developed for one disorder might be beneficial for the other, and possibly for autism and intellectual disability more broadly.
TSC mutations affect synaptic function
The choice of TSC was guided by several considerations. Like FXS, (1) TSC is a single-gene disorder with core symptoms of ASD and intellectual disability, (2) the affected gene(s) lie in a signalling pathway that couples cell surface receptors to mRNA translation, (3) there are well validated mouse models of the disease and (4) some mutant phenotypes in these mouse models have responded to pharmacological treatments that affect protein synthesis [4] [5] [6] . The disease is caused by heterozygous mutations in the genes encoding TSC1 or TSC2 proteins that together form the TSC1/2 complex. TSC1/2 acts to inhibit Rheb, a Ras family GTPase with high specificity for mTOR within a protein complex called mTORC1. Rheb activation of mTORC1 can stimulate mRNA translation and cell growth, and excessive mTORC1 activation is believed to be pathogenic in TSC 7 . TSC is characterized by the growth of hamartomas that are believed to result from inactivation of the functional allele within the tumour cells 8, 9 . Although some neurological manifestations of TSC are thought to be related to tumour growth in the cerebral cortex, others including cognitive impairment and autism have been proposed to result from abnormal signalling at synapses 10 . Consistent with this idea, mice engineered to carry heterozygous loss-of-function mutations in Tsc1 or Tsc2 have been shown to have hippocampus-dependent learning and memory deficits without having tumours in the brain or seizures 4, 11 . Here we chose the Tsc2 1/2 mouse model because TSC2 mutations are more common and produce a more severe phenotype in humans 12 , and this animal model is in widespread use 4, [13] [14] [15] . Of particular significance, postnatal treatment of Tsc2 1/2 mice with the mTORC1 inhibitor rapamycin was previously shown to ameliorate hippocampal memory impairments, suggesting the exciting possibility that some aspects of TSC, like FXS, might be amenable to drug therapy 4 .
A prominent hypothesis is that synaptic dysfunction in TSC relates to increased protein synthesis in response to elevated mTORC1 activity 16 . Signalling by mTORC1 has been suggested to contribute to the coupling of mGluR5 to protein synthesis and, although still controversial, it has been proposed that elevated mTOR activity might also be a cause of elevated protein synthesis in the Fmr1 2/y mouse 17 . A sensitive electrophysiological read-out of local mRNA translation in response to mGluR5 activation is long-term synaptic depression (LTD) in area CA1 of the hippocampus 18, 19 . Indeed, it was exaggerated LTD in the Fmr1 2/y mouse that led to the mGluR theory of FXS 20, 21 . Therefore, to test the hypothesis of a shared pathophysiology between TSC and FXS, we first examined mGluR-LTD in the hippocampus of male Tsc2 1/2 mice. in hippocampal slices 19 . Unexpectedly, we discovered that DHPGinduced LTD was deficient rather than enhanced in the hippocampus of Tsc2 1/2 mice, compared with wild-type (WT) controls ( Fig. 1a ). A similar deficit was observed when mGluR-LTD was induced by patterned electrical stimulation of Schaffer collateral synapses ( Fig. 1b ). In agreement with a previous report 4 , basal synaptic transmission in CA1 appeared normal in the Tsc2 1/2 mice, indicating that the impairment in mGluR-LTD is not due to general disruption of synaptic function ( Supplementary Fig. 1 ). Moreover, there was no difference in the magnitude of the NMDA (N-methyl-D-aspartate)receptor-dependent form of LTD between WT and Tsc2 1/2 mice ( Fig. 1c) , demonstrating that the deficit is specific to mGluR-LTD, as these same synapses are able to undergo activity-induced depression by a different mechanism. To test the possibility of a general disruption in Gp 1 mGluR function, we examined DHPG-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), a common measure of Gp1 mGluR signalling and a critical step for mGluR-mediated protein synthesis and LTD 22, 23 . Basal ERK1/2 phosphorylation and DHPG-induced increases in ERK1/2 phosphorylation are unaltered in Tsc2 1/2 mice ( Fig. 1d ). These results suggest that the deficit in mGluR-LTD seen in the Tsc2 1/2 hippocampus is not due to a global dysregulation of synaptic function or Gp 1 mGluR signalling. mGluR-LTD in area CA1 of the hippocampus is expressed by two independent mechanisms: reduced probability of presynaptic glutamate release [24] [25] [26] and reduced expression of postsynaptic AMPA receptors 25, 27 . In WT animals, the postsynaptic modification is known to require immediate translation of mRNAs available in the dendrites of hippocampal pyramidal neurons 18, 28 . Accordingly, we found that LTD in WT mice at the age range examined (postnatal day (P) [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] is reliably reduced by the protein synthesis inhibitor cycloheximide (60 mM; Fig. 2a ). The presynaptic component of LTD was monitored by measuring paired-pulse facilitation, which showed a persistent increase following DHPG that reflects reduced probability of glutamate released at the presynaptic terminal [24] [25] [26] . Changes in paired-pulse facilitation were not inhibited by cycloheximide ( Supplementary Fig. 2 and Fig. 2c ), suggesting that residual LTD in the presence of the drug is expressed presynaptically. Although LTD was reduced in Tsc2 1/2 mice, the persistent paired-pulse facilitation change after DHPG was no different than in WT, suggesting a deficient postsynaptic modification ( Supplementary Fig. 2 and Fig. 2c ). Indeed, unlike WT, cycloheximide treatment had no effect on LTD in the Tsc2 1/2 animals ( Fig. 2b) . These data suggest a selective loss of the protein-synthesisdependent component of LTD in the mutant mice.
These electrophysiological results in the Tsc2 1/2 hippocampus stand in stark contrast to the Fmr1 2/y mouse in which mGluR-LTD is exaggerated 20 . In the fragile X mouse model, increased LTD correlates with an increased rate of basal mRNA translation downstream of mGluR5. Therefore we were compelled to examine protein synthesis in hippocampal slices from the Tsc2 1/2 mouse as previously described for the Fmr1 2/y mouse 23 . Consistent with the mGluR-LTD findings, we found a small but significant decrease in [ 35 S]methionine/cysteine incorporation into protein under basal conditions in the hippocampus of Tsc2 1/2 mice (Fig. 2d ). This finding suggested the possibility that protein(s) required for mGluR-LTD are deficiently translated in the hippocampus of Tsc2 1/2 mice. To test this idea we examined levels of Arc, a plasticity-related protein that is rapidly synthesized in response to Gp 1 mGluR activation and is required for mGluR-LTD 29, 30 . Interestingly, we found that Arc expression is decreased in Tsc2 1/2 hippocampal slices ( Fig. 2e ). To determine whether this decrease was due to diminished translation, we measured the amount of newly synthesized Arc in Tsc2 1/2 slices by performing immunoprecipitation experiments on metabolically labelled slices (see Methods) 23 . Examination of the 35 S-incorporated fraction revealed a significant reduction in Arc translation in the hippocampus of Tsc2 1/2 mice ( Fig. 2f ). Control immunoprecipitations using non-immune IgG confirmed that our measurements were specific for Arc ( Supplementary  Fig. 4 ). These results suggest that mGluR-LTD is deficient in the Tsc2 1/2 hippocampus because of a decrease in the translation of the proteins required to stabilize LTD, including Arc.
LTD deficit caused by excess mTOR activity
As in the human disease, the germline mutation in Tsc2 can have myriad secondary consequences on neural development that could contribute to the observed LTD and protein synthesis phenotypes. To test the hypothesis that the deficient mGluR-LTD seen in Tsc2 1/2 mice is a specific consequence of unregulated mTOR activity, we examined the effects of the mTORC1 inhibitor rapamycin. We found that acute rapamycin treatment (20 nM) restored mGluR-LTD in the Tsc2 1/2 mice to WT levels ( Fig. 2g ), whereas this same treatment had no effect on mGluR-LTD in slices from WT mice ( Supplementary Fig. 3 ). This rescue is due specifically to the recovery of the protein-synthesisdependent component of LTD, as the effect of rapamycin in Tsc2 1/2 mice was eliminated in the presence of cycloheximide (Fig. 2h ). The same rapamycin treatment also restored basal protein synthesis rates in Tsc2 1/2 hippocampal slices back to WT levels (Fig. 2i ). The simple model that best fits the data is that unregulated mTOR activity caused by the Tsc2 1/2 mutation suppresses the protein synthesis that is required for mGluR-LTD ( Fig. 3a) . , is also deficient in slices from Tsc2 1/2 mice (WT: 65.1 6 2.1%, n 5 3 animals, 9 slices; Tsc2 1/2 : 85.0 6 2.5%, n 5 4 animals, 11 slices; *P 5 0.003). c, The magnitude of NMDA receptordependent LTD evoked by low-frequency stimulation (LFS, 900 pulses at 1 Hz) does not differ between genotypes (WT: 79.8 6 1.6%, n 5 4 animals, 6 slices; Tsc2 1/2 : 79.4 6 1.9%, n 5 6 animals, 6 slices; P 5 0.610). d, Hippocampal slices were stimulated with 50 mM DHPG for 5 min, and ERK1/2 activation (phosphorylation) assessed by immunoblot (normalized WT: 100.0 6 6.1%; WT DHPG: 119.6 6 5.5%; Tsc2 1/2 : 97.5 6 5.6%; Tsc2 1/2 DHPG: 116.2 6 3.9%; ANOVA: genotype P 5 0.623, treatment *P 5 0.0008, genotype 3 treatment P 5 0.923; n 5 9 animals). Results reveal that DHPG significantly increases ERK1/2 activation in both WT (*P 5 0.040) and Tsc2 1/2 (*P 5 0.003). Error bars, s.e.m.
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Effect of mGluR5-positive allosteric modulation
In the Fmr1 2/y model of FXS, excessive mGluR-LTD and hippocampal protein synthesis can be corrected by reducing signalling by mGluR5 23, 31 . We therefore wondered if the opposite approach of potentiating mGluR5 signalling with a positive allosteric modulator (PAM) could be beneficial in this model of TSC (Fig. 3a) . PAMs are compounds that do not activate mGluR5 directly but act on an allosteric site to potentiate physiological activation of the receptor 32 . Indeed, we found that pretreatment of hippocampal slices with the mGluR5 PAM 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB 33 ) restored the magnitude of mGluR-LTD in Tsc2 1/2 mice to WT levels (Fig. 3b ). The rescue of LTD appears to be due specifically to recovery of the protein-synthesis-dependent component because the effect of CDPPB was completely eliminated by cycloheximide ( Fig. 3c ). Consistent with this conclusion, CDPPB treatment also restored basal protein synthesis levels ( Fig. 3d ) and rescued the deficit in Arc synthesis in the Tsc2 1/2 mice (Fig. 3e ). Thus, allosteric augmentation of mGluR5 signalling can overcome the inhibitory effect of unregulated mTOR activity on the synaptic protein synthesis that supports LTD.
In an important recent study, cognitive impairments in the Tsc2 1/2 mice were shown to be significantly improved by treating the animals with the mTORC1 inhibitor rapamycin 4 . In light of our , CHX treatment has no effect on LTD in slices from Tsc2 1/2 mice (control: 86.3 6 3.1%, n 5 6 animals, 12 slices; CHX: 85.3 6 3.2%, n 5 4 animals, 7 slices, P 5 0.796). ANOVA: genotype *P 5 0.041, treatment P 5 0.089, genotype 3 treatment *P 5 0.045. c, Presynaptic LTD is not affected by genotype or CHX (see also Supplementary Fig. 2) . DHPG significantly increased paired-pulse facilitation in slices from both WT and Tsc2 1/2 mice (paired-pulse facilitation with a 50 ms inter-stimulus interval: WT baseline: 1.37 6 0.02, WT DHPG: 1.59 6 0.06, n 5 5 animals, 9 slices, *P 5 0.003; Tsc2 1/2 baseline: 1.39 6 0.02, Tsc2 1/2 DHPG: 1.64 6 0.03, n 5 5 animals, 9 slices, *P 5 0.001) and this effect was not blocked by CHX (WT DHPG 1 CHX: 1.58 6 0.06, n 5 7 animals, 11 slices, P 5 0.89; Tsc2 1/2 DHPG 1 CHX: 1.64 6 0.04, n 5 6 animals, 7 slices, P 5 0.94). d, Metabolic labelling of hippocampal slices reveals a significant reduction of basal protein synthesis in Tsc2 1/2 mice (WT: 100.0 6 3.1%, Tsc2 1/2 : 88.2 6 3.3%, n 5 13 animals; *P 5 0.043). Differences in protein synthesis are exemplified by representative autoradiograph and total protein stain of the same membrane. e, Immunoblotting experiments show that Arc expression is significantly reduced in Tsc2 1/2 hippocampal slices (WT:
100.0 6 4.7%, Tsc2 1/2 : 76.6 6 6.4%, n 5 12 animals; *P 5 0.005). f, Arc translation was measured by metabolic labelling of hippocampal slices, followed by immunoprecipitation of Arc. Comparison of the ratios of 35 Sincorporated-to-total Arc reveals a significant reduction in Arc translation in the Tsc2 1/2 hippocampus (WT: 100.0 6 11.5%, Tsc2 1/2 : 74.7 6 6.8%, n 5 19 animals; *P 5 0.049). g, Pretreatment of slices with the mTORC1 inhibitor rapamycin (RAP, 20 nM, grey bar) significantly enhances DHPG-induced LTD in slices from Tsc2 1/2 mice (dimethylsulphoxide (DMSO): 85.7 6 2.1%, n 5 8 animals, 17 slices; RAP: 72.9 6 1.8%, n 5 7 animals, 18 slices; *P 5 0.002). h, The rescue by rapamycin of DHPG-induced LTD in Tsc2 1/2 mice is prevented by the protein synthesis inhibitor cycloheximide (DMSO: 87.1 6 4.7%, n 5 6 animals, 10 slices; RAP: 88.1 6 2.4%, n 5 7 animals, 9 slices; P 5 0.796). ANOVA: rapamycin treatment *P 5 0.043, cycloheximide treatment *P 5 0.004, rapamycin 3 cycloheximide *P 5 0.018. i, Metabolic labelling experiments show that rapamycin (20 nM) normalizes protein synthesis in the Tsc2 1/2 hippocampus to WT levels (WT DMSO: 100.0 6 2.5%, WT RAP: 106.5 6 3.6%, Tsc2 1/2 DMSO: 88.8 6 2.6%, Tsc2 1/2 RAP: 100.4 6 3.9%; ANOVA: genotype *P 5 0.008, treatment *P 5 0.006, genotype 3 treatment P 5 0.430; t-test: WT compared with Tsc2 1/2 DMSO *P 5 0.003; WT compared with Tsc2 1/2 RAP P 5 0.344; Tsc2 1/2 DMSO compared with RAP *P 5 0.037; n 5 22 animals). Error bars, s.e.m.
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electrophysiological and biochemical findings, we wondered if a similar amelioration would be observed with the mGluR5 PAM. A robust phenotype was reported to be an impairment in the ability of the Tsc2 1/2 mice to distinguish between familiar and novel contexts in a fear conditioning task. Advantages of this task are that the learning occurs in one trial, making it amenable to acute drug treatment, and the memory is hippocampus dependent 34 . Although a requirement for CA1 LTD per se has not been established, contextual fear discrimination does depend on both mGluR5 35 and new protein synthesis at the time of training 36 . In this assay, mice are first exposed to a distinctive context in which they receive an aversive foot shock. The next day, context discrimination is tested by dividing the animals into two groups: one is placed in the familiar context associated with the shock; the other is placed in a novel context (Fig. 3f ). Context discrimination is assessed by measuring the time the animals express fear by freezing in each context. Although the WT mice clearly discriminate between contexts, the Tsc2 1/2 mice do not 4 (Fig. 3g) . To test the effect of augmenting mGluR5 signalling, mice from both genotypes were injected intraperitoneally with CDPPB (10 mg kg 21 ) 30 min before training. Although this treatment had no effect in the WT mice, it was sufficient to correct the deficit in context discrimination observed in the Tsc2 1/2 mice. These results show that augmentation of mGluR5 signalling is beneficial at the behavioural level in Tsc2 1/2 mice and that disrupted mGluR5 function may be relevant to cognitive impairments associated with TSC.
Fmr 2/y and Tsc2 1/2 mutations cancel each other Contrary to our initial hypothesis, we found that mutations causing FXS and TSC, two disorders associated with autism and intellectual disability, show mirror symmetrical alterations in protein-synthesisdependent LTD and have beneficial responses to treatments that modulate mGluR5 in opposite directions (Fig. 4a) . These findings raised the intriguing possibility that these two mutations could cancel one another on this functional axis. To test this hypothesis, we introduced an Fmr1 deletion into the Tsc2 1/2 background by crossing Tsc2 1/2 males with Fmr1 1/2 females (Fig. 4b ). This approach also enabled us to compare directly with WT the effects of the Tsc2 1/2 and Fmr1 2/y mutations in littermates reared under identical conditions. As expected, mGluR-LTD was diminished in Tsc2 1/2 mice and excessive in the Fmr1 2/y mice, compared with WT ( Fig. 4c,d) . However, mice harbouring both mutations showed mGluR-LTD that was indistinguishable from WT (Fig. 4c,d) .
Although Tsc2 1/2 and Fmr1 2/y mutations cause opposite alterations in mGluR-LTD and protein synthesis, the human disorders they are associated with have similar neurological and cognitive phenotypes. Might opposite deviations in synaptic function lead to shared cognitive impairments? To examine this question, we compared context discrimination in the Tsc2 1/2 and Fmr1 2/y mice and discovered that indeed they do share a deficit in this measure of memory (Fig. 4e) . Remarkably, instead of being exacerbated, this memory deficit was erased in the double mutants (Fig. 4e) . These results suggest that the c, CDPPB treatment fails to enhance DHPG-induced LTD in Tsc2 1/2 mice when co-applied with the protein synthesis inhibitor cycloheximide (DMSO: 89.0 6 4.4%, n 5 8 animals, 10 slices; CDPPB: 83.9 6 2.1%, n 5 7 animals, 9 slices; P 5 0.64). ANOVA: CDPPB treatment *P 5 0.008, CHX treatment P 5 0.087, CDPPB 3 CHX *P 5 0.034. d, CDPPB (10 mM) restores protein synthesis in the Tsc2 1/2 hippocampus to WT levels (WT DMSO: 100.0 6 3.2%, WT CDPPB: 97.2 6 1.9%, Tsc2 1/2 DMSO: 86.1 6 2.7%, Tsc2 1/2 CDPPB: 94.9 6 3.0%; ANOVA: genotype *P 5 0.006, treatment P 5 0.275, genotype 3 treatment *P 5 0.041; t-test: WT compared with Tsc2 1/2 DMSO *P 5 0.012; WT compared with Tsc2 1/2 CDPPB P 5 0.538; Tsc2 1/2 DMSO compared with CDPPB *P 5 0.049; n 5 17 animals). e, CDPPB exposure significantly increases Arc translation in the Tsc2 1/2 hippocampus (WT DMSO 100.0 6 28.2%, WT CDPPB 121.0 6 21.2%, Tsc2 1/2 DMSO 59.2 6 7.0%, Tsc2 1/2 CDPPB 129.4 6 20.3%; ANOVA genotype P 5 0.554, treatment *P 5 0.009, genotype 3 treatment P 5 0.114; t-test: Tsc2 1/2 DMSO compared with CDPPB *P 5 0.026; n 5 6 animals). Error bars, s.e.m. f, Experimental design of context discrimination task. g, WT mice display intact memory by freezing more in the familiar context than the novel context (black bars; familiar: 50 6 7.7%, n 5 12; novel: 34.1 6 3.2%, n 5 14; *P 5 0.003). A single injection of CDPPB (10 mg kg 21 , intraperitoneal) 30 min before training has no effect on WT context discrimination (familiar: 42.3 6 3.7%, n 5 12; novel: 26.4 6 3.6%, n 5 12; *P 5 0.005). Control Tsc2 1/2 mice display an impairment in context discrimination (blue bars; familiar: 40.9 6 5.3%, n 5 11; novel: 39.3 6 5.2%, n 5 14; P 5 0.501), but this deficit is corrected by a single injection of CDPPB (familiar: 44.5 6 4.3%, n 5 11; novel: 31.6 6 3%, n 5 12; *P 5 0.034). Error bars, s.e.m.
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opposing synaptic deviations seen in Tsc2 1/2 and Fmr1 2/y mice may manifest similarly at the behavioural level, as introducing both mutations not only reverses the disruptions of synaptic plasticity but rescues this memory impairment as well.
Discussion
LTD and protein synthesis downstream of mGluR5 have attracted attention in the context of several diseases, most notably FXS 27 .
Fragile X is caused by the loss of FMRP, an mRNA-binding protein that negatively regulates translation 37, 38 . In the Fmr1 2/y mouse model, basal protein synthesis is elevated and LTD is exaggerated downstream of an mGluR5 signalling pathway involving ERK1/2 (ref. 23) . Partial inhibition of mGluR5 corrects multiple aspects of fragile X in animal models 2, 39 . Recent data suggest that the mTOR signalling pathway is also constitutively overactive in the Fmr1 2/y mouse 17 , but the relevance to exaggerated protein synthesis and altered synaptic function has been unclear. The current findings show that increased synaptic mTOR activity actually suppresses the protein synthesis required for LTD in the Tsc2 1/2 mice. The idea that reduced protein synthesis is a causative factor in the observed deficit in synaptic plasticity is supported by the finding that pharmacological rescue with both rapamycin and CDPPB is abolished by cycloheximide, and the observation that Arc is deficiently translated in the Tsc2 1/2 mice. There is good evidence that Arc is one of the proteins that normally must be synthesized to support mGluR5-dependent forms of longterm plasticity 29, 30 . Precisely how excess mTOR activity suppresses synthesis of these plasticity proteins remains to be investigated, but possibilities include hyperphosphorylation of FMRP 40 or increased translation of a competing pool of less abundant mRNAs unrelated to LTD 7, 21, 30 . The fact that mGluR-LTD is altered in opposite directions in Tsc2 1/2 and Fmr1 2/y mice, and that both deviations are corrected in the double mutants, suggests that the pool comprising LTD proteins is differentially regulated by FMRP and TSC1/2 (Fig. 3a) .
The current findings also suggest a new treatment for behavioural deficits associated with TSC. Previous studies in the Tsc2 1/2 mouse raised the exciting possibility that cognitive aspects of the disorder might be ameliorated with rapamycin, even when treatment is begun in adulthood 4 . Our data show that an mGluR5 PAM may be similarly effective. Although rapamycin has been used clinically, it is problematic for chronic treatment because of its strong immunosuppressive properties. The benefit of mGluR5 PAMs is that they target specifically the synaptic mechanisms that are probably responsible for the cognitive and behavioural impairments in TSC.
TSC and FXS represent two leading genetic risk factors for ASD and intellectual disability 41 . Although great strides have been made in identifying genetic variation that correlates with non-syndromic autism, little is known about ASD pathophysiology, knowledge that is essential for developing effective therapies. Our test of the hypothesis that the Fmr1 2/y and Tsc2 1/2 models of FXS and TSC have a shared synaptic pathophysiology revealed instead that they are at opposite ends of a spectrum: the Fmr1 mutation causes exaggerated synaptic protein synthesis and LTD that are corrected by inhibition of mGluR5 (ref. 31 ), whereas the Tsc2 mutation causes diminished synaptic protein synthesis and LTD that are corrected by augmentation of mGluR5 (Fig. 4a) . Moreover, the opposing effects of these mutations balance one another at synaptic and behavioural levels in the double mutant. This finding is interesting in light of recent discoveries that gain-and loss-of-function mutations in individual genes, such as MECP2, can often yield syndromes with overlapping features, such as epilepsy, cognitive impairment and ASD 42 . Our findings reveal that even genetically heterogeneous causes of ASD and intellectual disability may produce similar deficits by bidirectional deviations from normal on a common functional axis. The important implication is that therapies designed to correct one cause of ASD are not likely to be effective for all other causes, and might well be deleterious. It will be critical to understand where a patient lies on the spectrum of synaptic function to choose an appropriate therapy for ASD and other psychiatric disorders.
METHODS SUMMARY
All experimental procedures were approved by the Institutional Animal Care and Use Committee at Massachusetts Institute of Technology. Age-matched, male littermate mice bred on the C57Bl/6J clonal background were used in this study. behavioural impairments present in both single mutants. a, The data suggest that optimal synaptic function requires a narrow and tightly regulated level of synaptic protein synthesis and that deviations in either direction can impair function 3, 43 . TSC and FXS fall on different ends of this spectrum and respond to opposite alterations of mGluR5 signalling. These results raise the possibility that introducing both mutations to a mouse may normalize aspects of neural function. b, Genetic rescue strategy. Heterozygous Tsc2 male mice (Tsc2 1/2 ) were bred with heterozygous Fmr1 females (Fmr1 x 1 /x -) to obtain male offspring of four genotypes: WT (Tsc2 1/1 , Fmr1 1/y ), Fmr1 KO (Tsc2 1/1 , Fmr1 2/y ), Tsc2 Het (Tsc2 1/2 , Fmr1 1/y ) and cross (Tsc2 1/2 , Fmr1 2/y ). c, DHPG-induced LTD is significantly decreased in slices from Tsc2 1/2 mice (*P 5 0.002) and significantly increased in slices from Fmr1 2/y mice (*P 5 0.017), compared with WT slices. DHPG-LTD in slices from Tsc2 1/2 3 Fmr1 2/y mice is comparable in magnitude to WT slices (P 5 0.558). (WT: 78.9 6 2.1%, n 5 7 animals, 17 slices; Fmr1: 71.2 6 2.7%, n 5 7 animals, 21 slices; Tsc2: 89.5 6 2.6%, n 5 7 animals, 15 slices; cross: 77.4 6 1.8%, n 5 9 animals, 19 slices). d, Summary of LTD data. Bar graphs, percentage decrease from baseline in fEPSP (average of last 5 min of recording 6 s.e.m.); *P , 0.05, **P , 0.01. e, Both mutations cause a deficit in context discrimination that is rescued in the double mutant. WT mice (familiar: 42.9 6 4.6%, n 5 11; novel: 27.8 6 3.4%, n 5 12; *P 5 0.024), Fmr1 2/y mice (familiar: 49.0 6 5.6%, n 5 11; novel: 43.5 6 6.7%, n 5 12; P 5 0.483), Tsc2 1/2 mice (familiar: 42.1 6 6.8%, n 5 12; novel: 35.6 6 6.0%, n 5 12; P 5 0.395) and Tsc2 1/2 3 Fmr1 2/y mice (familiar: 50.5 6 5.2%, n 5 11; novel: 29.8 6 5.2%, n 5 11; *P 5 0.011). Error bars, s.e.m.
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Acute hippocampal slices were prepared from P25-35 mice as previously described 31 and field excitatory postsynaptic potentials (fEPSPs) evoked by stimulation of the Schaffer collaterals were recorded in CA1 stratum radiatum with extracellular electrodes. LTD was induced by applying R,S-DHPG (50 mM) or S-DHPG (25 mM) for 5 min, or by paired-pulse low-frequency synaptic stimulation 18, 19 for 20 min. Metabolic labelling, immunoblotting and immunoprecipitation experiments were performed on yoked WT and Tsc2 1/2 mice as described previously 23, 43 . Context discrimination fear conditioning was performed as described previously 4 . For in vivo mGluR5 PAM experiments, animals received a single injection of CDPPB (10 mg kg 21 , intraperitoneal) 30 min before the training session. For all data sets, outliers more than 2s from the mean were removed, and significance between more than two groups was determined using two-way analysis of variance (ANOVA) and post hoc Student's t-tests. Statistics were performed using each animal as an 'n', with each animal represented by the mean of one to four slices for electrophysiology experiments, one slice per animal for biochemistry experiments and five to eight slices per animal for immunoprecipitation experiments. All experiments were performed blind to genotype and include interleaved controls for genotype and treatment. For detailed methods, see Supplementary Information.
